Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin with low-dose radiotherapy versus trabectedin alone in advanced sarcoma
2026-525703-27-00Phase 4Authorised
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Start
- Sep 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of trabectedin in soft tissue sarcoma (STS), osteosarcoma (OS) and Ewing sarcoma of bone (2 arms), sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. Primary endpoints: Objective response rate and Radiologic efficacy validation. Planned start Sep 2026; status: authorised.
02
Drugs
trabectedin
03
Conditions
soft tissue sarcoma (STS)osteosarcoma (OS)Ewing sarcoma of bone
Beyond the preview
Go deeper on 2026-525703-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525703-27-00.